0001735936-21-000003.txt : 20211230 0001735936-21-000003.hdr.sgml : 20211230 20211229193133 ACCESSION NUMBER: 0001735936-21-000003 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20211230 DATE AS OF CHANGE: 20211229 EFFECTIVENESS DATE: 20211230 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Osteal Therapeutics, Inc. CENTRAL INDEX KEY: 0001735936 IRS NUMBER: 900939060 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-427231 FILM NUMBER: 211530296 BUSINESS ADDRESS: STREET 1: 105 AVENIDA DE LA ESTRELLA STREET 2: SUITE 3 CITY: SAN CLEMENTE STATE: CA ZIP: 92672 BUSINESS PHONE: 650-691-5030 MAIL ADDRESS: STREET 1: 105 AVENIDA DE LA ESTRELLA STREET 2: SUITE 3 CITY: SAN CLEMENTE STATE: CA ZIP: 92672 FORMER COMPANY: FORMER CONFORMED NAME: Joint Purification Systems, Inc. DATE OF NAME CHANGE: 20180328 D 1 primary_doc.xml X0708 D LIVE 0001735936 Osteal Therapeutics, Inc. 2514 Hillside Drive Dallas TX TEXAS 75214 469-809-2630 DELAWARE Joint Purification Systems, Inc. Corporation true David Thompson c/o Osteal Therapeutics, Inc. 2514 Hillside Drive Dallas TX TEXAS 75214 Executive Officer Director Rushu Luo c/o Osteal Therapeutics, Inc. 2514 Hillside Drive Dallas TX TEXAS 75214 Director Brian de Beaubien c/o Osteal Therapeutics, Inc. 2514 Hillside Drive Dallas TX TEXAS 75214 Director Douglas Kohrs c/o Osteal Therapeutics, Inc. 2514 Hillside Drive Dallas TX TEXAS 75214 Director David Cash c/o Osteal Therapeutics, Inc. 2514 Hillside Drive Dallas TX TEXAS 75214 Director Noam Krantz c/o Osteal Therapeutics, Inc. 2514 Hillside Drive Dallas TX TEXAS 75214 Director Judson Cooper c/o Osteal Therapeutics, Inc. 2514 Hillside Drive Dallas TX TEXAS 75214 Director Pharmaceuticals Decline to Disclose 06b false 2021-12-17 false true false 0 32388935 30248730 2140205 Total amount sold consists of $20,919,457.11 new cash and $9,329,272.91 cancellation of indebtedness. false 59 0 0 0 false Osteal Therapeutics, Inc. /s/ David Thompson David Thompson CEO 2021-12-29